The thoracic oncology community is discussing a potential link between GLP-1 agonists, such as Ozempic and Mounjaro, and a reduction in lung cancer spread. Other conversations focus on the importance of identifying rare hereditary lung cancers, which constitute 1-3% of cases. Discussions from the ASCOMOS26 meeting also covered management of uncommon EGFR mutations and other rare drivers.
“GLP-1 drugs like Ozempic & Mounjaro just cut how often lung cancer spreads. By half.”
— @agingroy · GLP-1 Agonists · View post ↗
“Only 1–3% of lung cancers are hereditary, but identifying them has major implications for patients and their families.”
— @ChandrakanthMv · Hereditary Lung Cancer · View post ↗
“Long-term follow-up isn’t the end of a trial, it’s where the real conversation begins.”
— @NarjustFlorezMD · Clinical Trial Follow-up · View post ↗📌 Amplified by @KolPulseAI
The breast oncology community is discussing a treatment algorithm for systemic therapy in early-stage HR+/HER2- breast cancer shared by Dr. Yakup Ergün (@dr_yakupergun), covering sequencing considerations for agents including olaparib and CDK4/6 inhibitors in clinically ambiguous scenarios.
“Recommendations in gray areas reflect my own clinical judgment— eg. olaparib and CDK4/6 sequence”
— @dr_yakupergun · Therapy Sequencing · View post ↗📌 Amplified by @KolPulseAI
The GI oncology community is discussing results from #ESMOGI26, led by the phase III IRIGA trial, which found first-line FOLFIRINOX did not improve outcomes over mFOLFOX6 in HER2-negative advanced gastric/GEJ adenocarcinoma. Other key trial updates include the phase 3 KRYSTAL-10 trial, where adagrasib plus cetuximab failed to meet its PFS and OS endpoints in second-line KRAS G12C-mutated mCRC. In contrast, early data for the KRAS G12D inhibitor zoldonrasib plus chemotherapy showed promising ORR in first-line PDAC.
“the phase III IRIGA trial says: not in the overall population.”
— @DrRishabhOnco · IRIGA trial · View post ↗
“👉 adagrasib + cetuximab did not meet its dual primary endpoints of PFS and OS vs chemo ± anti-VEGF/R”
— @p_ciracimd · KRYSTAL-10 trial · View post ↗📌 Amplified by @KolPulseAI
“🧬 KRAS G12D is no longer an “undruggable” target.”
— @DraMartinezLago · KRAS G12D inhibition · View post ↗📌 Amplified by @KolPulseAI
The GU oncology community is discussing the recent FDA approval of adjuvant belzutifan with pembrolizumab for high-risk RCC, weighing the reduction in recurrences against increased grade 3 toxicity with immature overall survival data. Additionally, there is strong consensus on using PSMA PET/CT for staging high-risk prostate cancer, and interest in the A-DREAM trial's evaluation of ADT interruption.
“Adjuvant kidney cancer: adding belzutifan to pembro cuts recurrences, but there was increase in grade 3 toxicity and overall survival is still immature. Is the trade worth it?”
— @katy_beckermann · Adjuvant Belzutifan in RCC · View post ↗📌 Amplified by @KolPulseAI
“Now, 95% of the international panel agreed that PSMA PET/CT should be the staging tool in high-risk prostate cancer (strong consensus)”
— @DrMHofman · PSMA PET/CT Staging · View post ↗
“the key findings from the A-DREAM trial thatevaluated ADT interruption in patients with metastatic hormone-sensitive #prostatecancer who responded well to an androgen receptor pathway inhibitor”
— @GUOncologyNow · A-DREAM Trial · View post ↗📌 Amplified by @KolPulseAI
The myeloma/hematology community is discussing a new transcriptomic analysis of CASSIOPEIA trial data, which identified novel risk categories and refined the predictive value of MRD. A separate 20-year analysis of 845 clinical trials highlights the global expansion of research but also unequal patient access. A recent SEER analysis showing a steep decline in U.S. myeloma mortality is also a topic of conversation.
“Transcriptomic profiling of CASSIOPEIA pts identified 5 subtypes & 3 risk categories w/ 72-month PFS rates of 70%/51%/27% & refined value of MRD by identifying high-risk pts in whom MRD was insufficient to predict outcome:”
— @Myeloma_Doc · CASSIOPEIA risk stratification · View post ↗📌 Amplified by @KolPulseAI
“Our new USMIRC analysis evaluated 845 multiple myeloma clinical trials registered on https://t.co/M3vaaOWVX8 over the past 20 years, examining where trials are conducted, how they have evolved, and who has access to innovation.”
— @Abdallah81MD · Clinical trial landscape · View post ↗
“Why do most myeloma patients eventually relapse after CAR T therapy?”
— @YLeyfman · CAR-T relapse mechanisms · View post ↗📌 Amplified by @KolPulseAI
The hematology community is discussing the formal publication of the PRISM AML risk model in JCO, a new prognostic tool for patients treated with HMA and venetoclax that incorporates 17 clinical and genomic variables. Other topics include new EBMT guidelines for autologous and allogeneic transplantation in adult Hodgkin lymphoma, and a study finding female sex is associated with superior OS and PFS after CAR T-cell therapy for Large B-cell Lymphoma.
“PRISM incorporates 17 clinical & genomic variables into a prognostic risk model that is better than ELN-2024.”
— @LeukDocJZ · PRISM AML Risk Model · View post ↗
“Female sex is associated with superior outcomes in patients treated with CAR T-cell therapy for Large B-cell Lymphoma”
— @BilalAbidMD · CAR T-cell therapy outcomes · View post ↗
“Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party”
— @smbenlazar · Hodgkin Lymphoma Guidelines · View post ↗